Dr. Kirstie Lithgow

MD FRCPC

Pronouns: she/her

Positions

Clinical Assistant Professor

Cumming School of Medicine, Department of Medicine

Clinical Assisant Professor

Cumming School of Medicine, Department of Oncology

Clinical researcher

Hotchkiss Brain Institute, Integrative concussion research program

Clinician

Arthur J.E. Child Comprehensive Cancer Centre

Member

Arnie Charbonneau Cancer Institute

Contact information

kclithgo@ucalgary.ca

Preferred method of communication

Admin Assistant

Robyn Shouldice

Email: robyn.shouldice@ahs.ca

Office: 403.955.8328

Background

Biography

Kirstie Lithgow is an endocrinologist and Assistant Clinical Professor at the Cumming School of Medicine at the University of Calgary. She completed her medical school, internal medicine and endocrinology training in Calgary and following this, went on to pursue additional fellowship training in pituitary disease and neuroendocrine tumours in Birmingham, UK. Her clinical and research interests include pituitary tumours, neuroendocrine tumours, and improving care for patients impacted by endocrine cancer. She has over 20 peer reviewed publications and holds grant funding from the Canadian Neuroendocrine Tumour Society.

Research

Areas of Research

Area of Focus

Neuroendocrine tumours (Gastroenteropancreatic)

Summary of Research

My current areas of research focus include use of diagnostic imaging in surveillance of patients with GEP NET. We previously published data on longitudinal radiation exposure associated with long term surveillance schedules. Currently we are analyzing data related to use of functional imaging with Ga-68 DOTATATE PET CT and it’s role in the longitudinal surveillance of GEP NET including prognosticating recurrence. I hold grant funding from the Canadian Neuroendocrine Tumour Society (CNETs) to compare different formulations and delivery mechanisms of our first line treatment for GEP NET (somatostatin analogs) with respect to PFS and patient reported outcomes included treatment susceptibility. I am also the site lead on a multisite Canadian study assessing neurocognition in patients with Stage III/Stage IV neuroendocrine tumours (SNAPSHOT study).